Colchicine Does Not Reduce Abdominal Aortic Aneurysm Growth in a Mouse Model. (30th September 2022)
- Record Type:
- Journal Article
- Title:
- Colchicine Does Not Reduce Abdominal Aortic Aneurysm Growth in a Mouse Model. (30th September 2022)
- Main Title:
- Colchicine Does Not Reduce Abdominal Aortic Aneurysm Growth in a Mouse Model
- Authors:
- Phie, James
Thanigaimani, Shivshankar
Huynh, Pacific
Anbalagan, Raghuveeran
Moran, Corey S.
Kinobe, Robert
Moxon, Joseph V.
Field, Matt A.
Krishna, Smriti M.
Golledge, Jonathan - Other Names:
- Spartalis Michael Academic Editor.
- Abstract:
- Abstract : Background and Aims . The nacht domain, leucine-rich repeat, and pyrin domain-containing protein 3 (NLRP3) inflammasome is upregulated in human abdominal aortic aneurysm (AAA), but its pathogenic role is unclear. The aims of this study were firstly to examine whether the inflammasome was upregulated in a mouse model of AAA and secondly to test whether the inflammasome inhibitor colchicine limited AAA growth. Methods . AAA was induced in eight-week-old male C57BL6/J mice with topical application of elastase to the infrarenal aorta and oral 3-aminopropionitrile (E-BAPN). For aim one, inflammasome activation, abdominal aortic diameter, and rupture were compared between mice with AAA and sham controls. For aim two, 3 weeks after AAA induction, mice were randomly allocated to receive colchicine (n = 28, 0.2 mg/kg/d) or vehicle control (n = 29 ). The primary outcome was the rate of maximum aortic diameter increase measured by ultrasound over 13 weeks. Results . There was upregulation of NLRP3 markers interleukin- (IL-) 1 β (median, IQR; 15.67, 7.11-22.60 pg/mg protein versus 6.87, 4.54-11.60 pg/mg protein, p = .048 ) and caspase-1 (109, 83-155 relative luminosity units (RLU) versus 45, 38-65 RLU, p < .001 ) in AAA samples compared to controls. Aortic diameter increase over 80 days (mean difference, MD, 4.3 mm, 95% CI 3.3, 5.3, p < .001 ) was significantly greater in mice in which aneurysms were induced compared to sham controls. Colchicine did not significantly limitAbstract : Background and Aims . The nacht domain, leucine-rich repeat, and pyrin domain-containing protein 3 (NLRP3) inflammasome is upregulated in human abdominal aortic aneurysm (AAA), but its pathogenic role is unclear. The aims of this study were firstly to examine whether the inflammasome was upregulated in a mouse model of AAA and secondly to test whether the inflammasome inhibitor colchicine limited AAA growth. Methods . AAA was induced in eight-week-old male C57BL6/J mice with topical application of elastase to the infrarenal aorta and oral 3-aminopropionitrile (E-BAPN). For aim one, inflammasome activation, abdominal aortic diameter, and rupture were compared between mice with AAA and sham controls. For aim two, 3 weeks after AAA induction, mice were randomly allocated to receive colchicine (n = 28, 0.2 mg/kg/d) or vehicle control (n = 29 ). The primary outcome was the rate of maximum aortic diameter increase measured by ultrasound over 13 weeks. Results . There was upregulation of NLRP3 markers interleukin- (IL-) 1 β (median, IQR; 15.67, 7.11-22.60 pg/mg protein versus 6.87, 4.54-11.60 pg/mg protein, p = .048 ) and caspase-1 (109, 83-155 relative luminosity units (RLU) versus 45, 38-65 RLU, p < .001 ) in AAA samples compared to controls. Aortic diameter increase over 80 days (mean difference, MD, 4.3 mm, 95% CI 3.3, 5.3, p < .001 ) was significantly greater in mice in which aneurysms were induced compared to sham controls. Colchicine did not significantly limit aortic diameter increase over 80 days (MD -0.1 mm, 95% CI -1.1, 0.86, p = .922 ). Conclusions . The inflammasome was activated in this mouse model of AAA; however, daily oral administration of colchicine did not limit AAA growth. … (more)
- Is Part Of:
- Cardiovascular therapeutics. Volume 2022(2022)
- Journal:
- Cardiovascular therapeutics
- Issue:
- Volume 2022(2022)
- Issue Display:
- Volume 2022, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 2022
- Issue:
- 2022
- Issue Sort Value:
- 2022-2022-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-09-30
- Subjects:
- Cardiovascular pharmacology -- Periodicals
Cardiovascular agents -- Periodicals
Cardiovascular system -- Diseases -- Chemotherapy -- Periodicals
Cardiovascular Agents -- Periodicals
Cardiovascular Diseases -- drug therapy -- Periodicals
Agents cardiovasculaires -- Périodiques
Appareil cardiovasculaire -- Maladies -- Chimiothérapie -- Périodiques
616.1005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1755-5922 ↗
http://www.blackwell-synergy.com/loi/cath ↗
http://www.blackwellpublishing.com/journal.asp?ref=1755-5914&site=1 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1155/2022/5299370 ↗
- Languages:
- English
- ISSNs:
- 1755-5914
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3051.520500
British Library HMNTS - ELD Digital store - Ingest File:
- 24092.xml